(Q46701530)

24 December 2017

title

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial (English)

1 reference

24 December 2017

0 references

0 references

C Pan

1

1 reference

24 December 2017

W Yang

2

1 reference

24 December 2017

J P Barona

3

1 reference

24 December 2017

Y Wang

4

1 reference

24 December 2017

M Niggli

5

1 reference

24 December 2017

P Mohideen

6

1 reference

24 December 2017

Y Wang

7

1 reference

24 December 2017

J E Foley

8

1 reference

24 December 2017

publication date

13 March 2008

1 reference

24 December 2017

published in

Diabetic Medicine

1 reference

24 December 2017

volume

25

1 reference

24 December 2017

page(s)

435-441

1 reference

24 December 2017

issue

4

1 reference

24 December 2017

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2008.02391.X

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2008.02391.X

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2008.02391.X

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2008.02391.X

Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2008.02391.X

Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2008.02391.X

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2008.02391.X

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2008.02391.X

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2008.02391.X

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2008.02391.X

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2008.02391.X

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2008.02391.X

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2008.02391.X

Postprandial hyperglycaemia and alpha-glucosidase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2008.02391.X

Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2008.02391.X

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2008.02391.X

Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2008.02391.X

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2008.02391.X

10.1111/J.1464-5491.2008.02391.X

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

PubMed ID

18341596

1 reference

24 December 2017